Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib + fulvestrant in EGFR-mutated advanced non-small cell lung cancer after prior reversible EGFR TKI failure
2012-000345-12Phase 2Active
- Sponsor
- Amsterdam University Medical Center
- Start
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gefitinib and fulvestrant in non-small cell lung cancer (NSCLC), sponsored by Amsterdam University Medical Center. Primary endpoint: Rate of no progression at 8 weeks. Started Mar 2012; status: active.
02
Drugs
gefitinibfulvestrant
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2012-000345-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000345-12.